Portfolio launch readiness
6 products in market or inside their launch window. Status rolls up automatically from the five readiness pillars — Market Access & Evidence and Regulatory, Supply & Product block a launch, the other three are advisory.
Product
Country
Showing the whole portfolio
Launches tracked
46
6 products
Every product and country in the programme.
On track
38
83%
Click to see these launches
At risk
7
15%
A pillar has gone amber. Launch is not blocked.
Click to see these launches
What is being done to de-risk →
Off track
1
2%
Market Access or Regulatory is red. Launch is blocked until it clears.
Click to see these launches
What is being done to recover →
Revenue at risk
$559M
4% of the $12.9B year-one forecast in scope
Blocked $67M
At risk $492M
Protected $12.3B
$67M sits behind launches that are blocked outright, and $492M behind launches carrying an open amber pillar.
Exposure assumes 60% of year-one revenue is at stake on an off-track launch and 25% on an at-risk launch.
Top 5 contributors
Zasocitinib — 2027 · France
$99M
At risk · launches in 329 days · $395M forecast
Zasocitinib — 2027 · Japan
$93M
At risk · launches in 268 days · $371M forecast
Rusfertide — 2026 · Germany
$81M
At risk · launches in 72 days · $324M forecast
Fazirsiran — AATD liver disease · Japan
$75M
At risk · launches in 300 days · $299M forecast
Where your attention is needed
1 launch is blocked by a red Market Access or Regulatory pillar. Each one needs a named decision this week.
Blocking pillars first, then the nearest launch date
Critical
Zasocitinib — 2027 — Germany · Market Access & Evidence
Launches in 286 days
G-BA / IQWiG issued a negative preliminary recommendation on the submitted dossier. Launch is blocked until this clears.
View launch
Why this matters
Medium
Rusfertide — 2026 — Germany · Market Access & Evidence
Launches in 72 days
G-BA / IQWiG has not yet scheduled a committee slot. The review window is slipping.
View launch
Why this matters
Medium
Mezagitamab — IgAN — United Kingdom · Market Access & Evidence
Launches in 265 days
NICE has not yet scheduled a committee slot. The review window is slipping.
View launch
Why this matters
Medium
Zasocitinib — 2027 — Japan · Market Access & Evidence
Launches in 268 days
Chuikyo has not yet scheduled a committee slot. The review window is slipping.
View launch
Why this matters
Medium
Elritercept — MDS anemia — United Kingdom · Market Access & Evidence
Launches in 270 days
NICE has not yet scheduled a committee slot. The review window is slipping.
View launch
Why this matters
Products
Select a product to see its countries